Logo (pure-white background + navy borde
  • YouTube
  • Facebook
  • Twitter
  • Instagram

© 2020 Diverse Health Hub, LLC

Andrew Campbell, MD

Director, Comprehensive Sickle Cell Program

Children’s National Health System


Director of the Consortium for the Advancement of Sickle Cell Disease Research (CASiRe)

Dr. Andrew Campbell is the Director of the Comprehensive Sickle Cell Program at Children’s National Health System in Washington DC. Dr. Campbell also serves as Director of the Consortium for the Advancement of Sickle Cell Disease Research (CASiRe).


Dr. Campbell is a graduate of Case Western Reserve School of Medicine and completed his residency training at Harvard Affiliated Massachusetts General Hospital in Boston followed by his Pediatric Hematology/Oncology Fellowship at Northwestern University.

Video Appearances

Can Patients and Providers Eliminate Health Inequities in Treating Sickle Cell Disease?

Program bullet points:

Communities, patients, and providers can eliminate health inequities in SCD.

Reach out to CBOs, industry stake holders, and government.

There are disparities in treatment for adult patients versus youth living with the disease.

Will New Sickle Cell Disease Drugs Transform Quality of Care for Patients?

Program bullet points:

Universal Drug Use: Many prior approved drugs were only made for patients in the United States

Voxelotor (Oxbryta): A game changer, increases hemoglobin levels in some patients

Multi-drug Treatment: More drug options allow for more personalized approaches

Multinational CASiRe - Will Sickle Cell Disease Clinicians & Trials Consider Diverse Populations?

Program bullet points:

The CASiRe Consortium International Cohort: Research around nearly 900 patients with SCD; goal to inform clinicians and other key stakeholders to consider racial and environmental factors in trials and treatments

Profiles of SCD Patients: Ghana, Italy, UK, US

Across the Globe: SCD not always embraced; thought to be Black